Work

Abstract CT103: Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies

Year: 2014

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2014-ct103

Authors: Eytan Stein, Martin Tallman, Daniel A. Pollyea, Ian W. Flinn, Amir T. Fathi, Richard M. Stone, Ross L. Levine, Samuel Agresta, David Schenkein, Hua Yang, Bin Fan, Kate Yen, Stephane D. Botton

Institutions: Memorial Sloan Kettering Cancer Center, University of Colorado Cancer Center, Sarah Cannon, Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Agios Pharmaceuticals (United States), Institut Gustave Roussy

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2053860390

Cites:

Cited by: 34

Related to: 10